Omada Health - OMDA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $26.33
  • Forecasted Upside: 51.43%
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$17.39
▲ +1.26 (7.81%)

This chart shows the closing price for OMDA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Omada Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OMDA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OMDA

Analyst Price Target is $26.33
▲ +51.43% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Omada Health in the last 3 months. The average price target is $26.33, with a high forecast of $29.00 and a low forecast of $19.00. The average price target represents a 51.43% upside from the last price of $17.39.

This chart shows the closing price for OMDA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 11 polled investment analysts is to moderate buy stock in Omada Health. This rating has held steady since August 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/5/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 1 sell ratings
11/4/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 1 sell ratings
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/13/2025BMO Capital MarketsInitiated CoverageOutperform$27.00
11/7/2025BarclaysBoost TargetOverweight ➝ Overweight$28.00 ➝ $29.00
11/7/2025Evercore ISIBoost TargetOutperform ➝ Outperform$27.00 ➝ $28.00
11/7/2025Needham & Company LLCBoost TargetBuy ➝ Buy$26.00 ➝ $28.00
10/22/2025BarclaysBoost TargetOverweight ➝ Overweight$24.00 ➝ $28.00
10/8/2025Evercore ISISet Target$27.00
10/8/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
9/27/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
9/5/2025Baird R WUpgradeHold
9/5/2025Robert W. BairdInitiated CoverageNeutral$24.00
8/8/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$27.00 ➝ $28.00
8/8/2025BarclaysBoost TargetOverweight ➝ Overweight$21.00 ➝ $24.00
8/8/2025Needham & Company LLCBoost TargetBuy ➝ Buy$23.00 ➝ $24.00
7/9/2025Evercore ISIBoost TargetOutperform ➝ Outperform$21.00 ➝ $23.00
7/1/2025Evercore ISIInitiated CoverageOutperform$21.00
7/1/2025Morgan StanleyInitiated CoverageOverweight$25.00
7/1/2025JPMorgan Chase & Co.Initiated CoverageOverweight$19.00
7/1/2025BarclaysInitiated CoverageOverweight$21.00
7/1/2025Needham & Company LLCInitiated CoverageBuy$23.00
7/1/2025The Goldman Sachs GroupInitiated CoverageBuy$29.00
7/1/2025Canaccord Genuity GroupInitiated CoverageBuy$27.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.73 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2025
  • 3 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2025
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/6/2025
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/5/2025
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/5/2025
  • 7 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/4/2025
  • 12 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/4/2025

Current Sentiment

  • 12 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Omada Health logo
Omada’s mission is to bend the curve. Our hope is that, one day, tomorrow’s epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms. We deliver virtual care between doctor’s visits, providing an engaging, personalized, and integrated experience for our members that is designed to improve their health while delivering value for the employers, health plans, health systems, pharmacy benefit managers (“PBMs”), and other entities that cover the cost of our programs. As of 2022, more than 156 million Americans suffered from one or more chronic conditions, such as obesity, prediabetes, diabetes, hypertension, and musculoskeletal (“MSK”) conditions, and approximately 40% of U.S. adults suffered from two or more chronic conditions, based on data published in the Annals of Bioethics & Clinical Applications. Managing these conditions—and treating the acute problems they can lead to—creates significant costs for employers, health plans, PBMs, and other entities that pay for the cost of care. According to the American Diabetes Association (the “ADA”)’s report “Economic Costs of Diabetes in the U.S. in 2022,” chronic diseases were the leading driver of U.S. medical spend, with diabetes alone accounting for $1 out of every $7 spent. According to research published in Diabetes Care, in 2022, an employee with type 2 diabetes cost on average an additional $7,000 annually due to increased medical costs, absenteeism, and lost productivity. The direct medical cost of people living with diabetes increased by 35% from 2012 to 2022, despite stable diabetes prevalence. It doesn’t have to be that way. Many chronic conditions can be managed or prevented at a more reasonable cost. One reason these conditions are often not managed efficiently is that the U.S. healthcare system was built mainly on encounter-based reimbursement models that pay for specific services, primarily as issues arise. Between what can be short and infrequent office visits, patients are often left to manage their condition on their own. Many have a hard time sticking to care plans and health goals—losing weight, eating better, exercising more—and have few resources to turn to for ongoing questions, accountability, and support as they work to change their lifestyle. Behavior change is hard. Omada was created to make it easier. Our virtual care programs are rooted in evidence and combine relationship-based, human-led clinical care with purpose-built technology. We call this approach Compassionate Intelligence. We work to develop trust with each member and use technology to help us personalize their experience, enabling us to unlock results at scale. We sell our programs to customers that cover the cost for covered individuals. Our customers include employers that cover our programs for their employees and their dependents, health systems that cover our programs for patients, and any other entity that is financially responsible for costs of our programs for a population of covered lives. We also work closely with health plans and PBMs that either cover our programs for a portion of their members as our customers or act as channel partners reselling our programs to their own end customers. Our channel partners’ end customers typically consist of employers that cover our programs for their employees and their dependents. In general, our customers cover the cost of our programs for our members, except that members in our physical therapy program may incur copays, coinsurance, or deductibles, depending on plan design, much like in-person physical therapy. We launched our initial program in diabetes prevention and weight health in 2012, with the goal of showing that a virtual program could achieve the same clinical results as its in-person archetype. Through feedback from our customers, channel partners, members, and the market at large, we then recognized the need to create an integrated, multi-condition care platform to address multiple, commonly comorbid, chronic conditions. Today, we offer cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address MSK conditions; additional support for members taking glucagon-like peptide-1 agonists (“GLP-1”) in our cardiometabolic programs (“GLP-1 Care Tracks”); and behavioral health support across all programs. Since our founding, our programs have had a meaningful, positive impact. As of March 31, 2025, we had more than 2,000 customers and over 679,000 total members enrolled in one or more programs, and we had supported over one million members since launch. We count a member as enrolled in a program to the extent their participation was billed at least once in the preceding 12 months. We believe our programs serve a clear need for our customers and channel partners as well as our members, which is reinforced by our strong customer satisfaction and member engagement rates. In 2024, our average customer satisfaction rate for the year was over 90% for each of program implementation and customer success. Our customer satisfaction rate is based on survey results from customers that launched a new program during the measured period, and we consider a customer to be satisfied if they rated our program implementation and ongoing customer success, as applicable, at a 5 or higher on a 7-point scale. We believe that our customer satisfaction rates are strong and reflect the value of our services to customers. In 2024, more than 55% of members still engaged with our cardiometabolic programs at least once per month after a year in the program, and over 50% still engaged monthly after two years. We consider members to be still engaged after one year or two years in the program if, during their twelfth or twenty-fourth month of program participation in a cardiometabolic program, they complete at least one interaction with us, such as logging in or interacting with the Omada mobile app, sending messages to Omada Care Team members, or recording metrics such as weight, blood pressure, or blood glucose values. On average, in 2024, members in a cardiometabolic program engaged more than 30 times per month throughout their first year. Based on our experience and feedback from customers, we believe these engagement rates to be positive and to demonstrate the attractiveness of our program to members. We are proud of our progress, and we are just getting started. We have experienced strong growth since our inception. Revenue increased by 38% from $122.8 million to $169.8 million for the years ended December 31, 2023 and 2024, respectively, and by 57% from $35.1 million to $55.0 million for the three months ended March 31, 2024 and 2025, respectively. We continue to generate revenue from recurring customers, as evidenced by our net dollar retention rate, which for customers who were contracted as of the beginning of the prior period, is calculated as total billings generated in a particular period divided by total billings generated in the prior period and was 110% and 128% for the years ended December 31, 2023 and 2024, respectively. We have a history of net losses, due in part to the significant investments we have made in the design and development of our programs and platform enhancements, and have not yet achieved profitability on an annual basis. Our principal executive offices are located San Francisco, California.
Read More

Today's Range

Now: $17.39
Low: $15.93
High: $17.53

50 Day Range

MA: $22.13
Low: $16.13
High: $26.78

52 Week Range

Now: $17.39
Low: $14.14
High: $28.40

Volume

2,175,330 shs

Average Volume

900,408 shs

Market Capitalization

$1.01 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Omada Health?

The following equities research analysts have issued research reports on Omada Health in the last year: Baird R W, Barclays PLC, BMO Capital Markets, Canaccord Genuity Group Inc., Evercore ISI, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Robert W. Baird, The Goldman Sachs Group, Inc., Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for OMDA.

What is the current price target for Omada Health?

0 Wall Street analysts have set twelve-month price targets for Omada Health in the last year. Their average twelve-month price target is $26.33, suggesting a possible upside of 51.4%. Barclays PLC has the highest price target set, predicting OMDA will reach $29.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $19.00 for Omada Health in the next year.
View the latest price targets for OMDA.

What is the current consensus analyst rating for Omada Health?

Omada Health currently has 1 sell rating, 2 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for OMDA.

What other companies compete with Omada Health?

How do I contact Omada Health's investor relations team?

Omada Health's physical mailing address is 500 SANSOME STREET, SUITE 200, SAN FRANCISCO, CA, 94111. The company's listed phone number is (888) 987-8337. The official website for Omada Health is www.omadahealth.com. Learn More about contacing Omada Health investor relations.